Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference

9/16/24 4:05:00 PM ET

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

Get the next $SLNO alert in real time by email

REDWOOD CITY, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will present at the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024, at 8:00 AM Eastern Time.

A live audio webcast and replay of the presentation will be available in the Investors section on the Company's website at www.soleno.life.

About Soleno Therapeutics, Inc.

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS) is currently under review by the FDA and was granted Priority Review. For more information, please visit www.soleno.life.

Corporate Contact:

Brian Ritchie

LifeSci Advisors, LLC

212-915-2578

Get the next $SLNO alert in real time by email

Date	Price Target	Rating	Analyst
9/3/2024	$70.00	Buy	H.C. Wainwright
5/10/2024	$72.00	Outperform	Robert W. Baird
2/5/2024	$93.00	Overweight	Piper Sandler
1/23/2024	$63.00	Buy	Stifel
11/21/2023	$40.00	Buy	Guggenheim

Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Chat with this insight

Recent Analyst Ratings for $SLNO

$SLNO Press Releases

Fastest customizable press release news feed in the world

Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Soleno Therapeutics to Participate in Upcoming November Investor Conferences

$SLNO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Officer Yen Kristen sold $153,627 worth of shares (3,108 units at $49.43), decreasing direct ownership by 4% to 81,465 units (SEC Form 4)

CHIEF FINANCIAL OFFICER Mackaness James H sold $399,241 worth of shares (8,077 units at $49.43), decreasing direct ownership by 6% to 119,172 units (SEC Form 4)

Officer Hirano Patricia C sold $153,627 worth of shares (3,108 units at $49.43), decreasing direct ownership by 3% to 108,932 units (SEC Form 4)

$SLNO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Perceptive Advisors Llc bought $15,113,916 worth of shares (866,789 units at $17.44) (SEC Form 4)

$SLNO SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Soleno Therapeutics Inc.

Soleno Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Soleno Therapeutics Inc.

$SLNO Market Insights

Live Market Insights

Soleno Therapeutics Submits NDA To The U.S. FDA For DCCR (Diazoxide Choline) Extended-Release Tablets For The Treatment Of Prader-Willi Syndrome

Soleno Therapeutics Set To Join Russell 3000 Index, Effective At The Open Of Us Equity Markets On Monday, July 1, 2024

Nvidia Is Up 186% From A Year Ago, Yet These 7 Stocks Have More Than Doubled Their Returns Over The AI Chipmaker

$SLNO Leadership Updates

Live Leadership Updates

Soleno Therapeutics Set to Join Russell 3000® Index

Soleno Therapeutics Strengthens Leadership Team with Key Appointments

Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors

$SLNO Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Soleno Therapeutics Inc.

$SLNO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on Soleno Therapeutics with a new price target

Robert W. Baird initiated coverage on Soleno Therapeutics with a new price target

Piper Sandler initiated coverage on Soleno Therapeutics with a new price target

$SLNO Financials

Live finance-specific insights

Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

Recent Analyst Ratings for
$SLNO

$SLNO
Press Releases

$SLNO
Insider Trading

$SLNO
Insider Purchases

$SLNO
SEC Filings

$SLNO
Market Insights

$SLNO
Leadership Updates

$SLNO
Large Ownership Changes

$SLNO
Analyst Ratings

$SLNO
Financials